PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Heron Therapeutics, Inc. (HRTX)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

US4277461020

CUSIP

427746102

Sector

Healthcare

IPO Date

Aug 26, 1987

Highlights

Market Cap

$250.96M

EPS (TTM)

-$0.16

PEG Ratio

-0.18

Total Revenue (TTM)

$147.20M

Gross Profit (TTM)

$99.43M

EBITDA (TTM)

-$22.21M

Year Range

$1.04 - $3.93

Target Price

$6.00

Short %

23.40%

Short Ratio

14.20

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Popular comparisons:
HRTX vs. XBI HRTX vs. NVDA HRTX vs. SGMO
Popular comparisons:
HRTX vs. XBI HRTX vs. NVDA HRTX vs. SGMO

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Heron Therapeutics, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


0.00%500.00%1,000.00%1,500.00%JulyAugustSeptemberOctoberNovemberDecember
-99.73%
1,672.68%
HRTX (Heron Therapeutics, Inc.)
Benchmark (^GSPC)

Returns By Period

Heron Therapeutics, Inc. had a return of -7.06% year-to-date (YTD) and -9.20% in the last 12 months. Over the past 10 years, Heron Therapeutics, Inc. had an annualized return of -16.65%, while the S&P 500 had an annualized return of 11.06%, indicating that Heron Therapeutics, Inc. did not perform as well as the benchmark.


HRTX

YTD

-7.06%

1M

41.07%

6M

-51.08%

1Y

-9.20%

5Y*

-42.26%

10Y*

-16.65%

^GSPC (Benchmark)

YTD

24.34%

1M

0.23%

6M

8.53%

1Y

24.95%

5Y*

13.01%

10Y*

11.06%

Monthly Returns

The table below presents the monthly returns of HRTX, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
202441.76%10.37%4.14%-16.25%59.48%-5.41%-15.14%-35.02%3.11%-12.56%-31.61%-7.06%
20238.40%-12.55%-36.29%58.28%-52.30%1.75%43.10%-1.20%-37.20%-38.17%93.12%38.21%-32.00%
2022-4.60%-18.48%-19.44%-20.98%-26.99%-15.45%-0.36%47.12%3.18%-8.77%-29.61%-7.75%-72.62%
2021-17.98%4.15%-10.34%7.83%-24.08%16.96%-20.36%-5.58%-8.40%2.99%-14.17%-3.39%-56.86%
2020-11.23%-10.59%-37.05%21.47%27.77%-19.26%10.74%-12.22%3.64%10.05%6.25%22.13%-9.94%
20193.70%-1.60%-7.67%-11.29%-21.45%9.16%-6.19%6.19%-0.11%14.86%20.28%-8.06%-9.41%
201819.61%-6.00%35.63%9.78%7.59%19.17%-3.60%2.94%-17.90%-12.29%3.49%-9.71%43.31%
2017-0.76%10.00%4.90%2.33%-12.70%3.36%14.44%4.10%-2.12%-4.95%14.66%2.84%38.17%
2016-21.39%-24.34%19.58%12.90%-0.19%-15.65%-7.92%11.91%-7.37%-13.81%3.37%-14.66%-50.94%
2015-21.47%64.43%12.01%-25.77%82.96%57.69%3.79%18.92%-36.56%12.38%9.23%-10.85%165.41%
201436.97%15.09%-0.86%-13.37%-0.91%3.18%-28.65%6.83%-11.29%5.88%-12.59%30.48%13.03%
201348.44%-13.47%-47.14%-1.62%13.21%-12.89%29.53%-11.83%-18.29%37.31%0.00%-3.26%-18.35%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of HRTX is 50, indicating average performance compared to other stocks on our website. Here’s a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of HRTX is 5050
Overall Rank
The Sharpe Ratio Rank of HRTX is 4747
Sharpe Ratio Rank
The Sortino Ratio Rank of HRTX is 5454
Sortino Ratio Rank
The Omega Ratio Rank of HRTX is 5454
Omega Ratio Rank
The Calmar Ratio Rank of HRTX is 4747
Calmar Ratio Rank
The Martin Ratio Rank of HRTX is 4747
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Heron Therapeutics, Inc. (HRTX) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


Sharpe ratio
The chart of Sharpe ratio for HRTX, currently valued at -0.03, compared to the broader market-4.00-2.000.002.00-0.032.10
The chart of Sortino ratio for HRTX, currently valued at 0.69, compared to the broader market-4.00-2.000.002.004.000.692.80
The chart of Omega ratio for HRTX, currently valued at 1.09, compared to the broader market0.501.001.502.001.091.39
The chart of Calmar ratio for HRTX, currently valued at -0.02, compared to the broader market0.002.004.006.00-0.023.09
The chart of Martin ratio for HRTX, currently valued at -0.07, compared to the broader market-5.000.005.0010.0015.0020.0025.00-0.0713.49
HRTX
^GSPC

The current Heron Therapeutics, Inc. Sharpe ratio is -0.03. This value is calculated based on the past 1 year of trading data and takes into account price changes and dividends.

Use the chart below to compare the Sharpe ratio of Heron Therapeutics, Inc. with the selected benchmark, providing insights into the investment's historical performance in terms of risk-adjusted returns. Go to the Sharpe ratio tool for more fine-grained control over the calculation options.


Rolling 12-month Sharpe Ratio0.001.002.003.00JulyAugustSeptemberOctoberNovemberDecember
-0.03
2.10
HRTX (Heron Therapeutics, Inc.)
Benchmark (^GSPC)

Dividends

Dividend History


Heron Therapeutics, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%JulyAugustSeptemberOctoberNovemberDecember
-99.88%
-2.62%
HRTX (Heron Therapeutics, Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Heron Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Heron Therapeutics, Inc. was 99.96%, occurring on Nov 14, 2023. The portfolio has not yet recovered.

The current Heron Therapeutics, Inc. drawdown is 99.88%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-99.96%Jan 14, 19928018Nov 14, 2023
-80.68%Sep 28, 1987787Nov 7, 1990290Jan 2, 19921077
-9.3%Sep 16, 19871Sep 16, 19875Sep 23, 19876
-4.76%Sep 1, 19873Sep 3, 19873Sep 9, 19876
-1.69%Aug 28, 19871Aug 28, 19871Aug 31, 19872

Volatility

Volatility Chart

The current Heron Therapeutics, Inc. volatility is 38.30%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%10.00%20.00%30.00%40.00%50.00%JulyAugustSeptemberOctoberNovemberDecember
38.30%
3.79%
HRTX (Heron Therapeutics, Inc.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Heron Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Historical P/E Ratio Chart

The chart below displays the historical trend of the price-to-earnings (P/E) ratio for Heron Therapeutics, Inc..


Loading data...

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2024 PortfoliosLab